The discovery of monoclonal antibodies has definitely opened a new perspective for the clinical handling of various disease. However, the fact that mAbs are generally derived in heterogeneous animals has led to many critical issues in safety and efficacy. Antibody chimeras were developed to circumvent these the problems by fusing heterogeneous V regions with human constant domain, but the resulting antibodies still carry a large stretch of non-human protein, which poses as potential risks in terms of in vivo application, e.g. human anti-chimeric antibody (HACA). Therefore, attempts were made to generate structures more similar to human antibodies, or humanization strategies. It is primarily done by transplanting the hypervariable loops of a fully human antibody backbone, with those of a non-human antibody of interest, via an approach called complementarity-determining region (CDR) grafting. Assisted by technical advances in molecular biology and computational modeling, it's now becomes possible to minimize immunogenicity concerns while maximally preserving original specificity & affinity.
Humanized antibodies still play a dominant and active part in biotherapeutic market, many of which are very classic and renowned antibody drugs. IgClue has included a full line of humanized therapeutic antibodies to support various in vitro/in vivo studies of today’s researchers.
IgClue is dedicated in presenting the most satisfactory antibody products & services to facilitate your research progress. If you have any questions or requests, please contact our tech team, and we will be happy to tailor a customized product for you.
Browse all humanized antibody products